Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

Tiffany A. Traina, MD, FASCO, discusses incorporating T-DXd and biomarkers into early-stage HER2-positive breast cancer treatment.

Lauren Banks, MD, PhD, discusses feasibility findings for lifileucel in select metastatic sarcomas and next steps with the phase 2 SARATOGA trial.

Thoracic oncologists discuss HER2 testing, frontline treatment selection, and resistance mechanisms in HER2-altered non–small cell lung cancer.

The top 5 OncLive TV videos of the week cover insights in CRC at ESMO 2026, dMMR rectal cancer, chronic neutropenia, pediatric LGG, and MSS CRC.

Thoracic oncologists weigh how TROP2-directed antibody-drug conjugates fit into sequencing and combination strategies for EGFR-mutated NSCLC.

Andrea Cercek, MD, discusses the FDA approval of dostarlimab and its significance for dMMR locally advanced rectal cancer management.

Andrea Cercek, MD, discusses the significance of the FDA approval of dostarlimab for dMMR/MSI-H locally advanced rectal cancer.

Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.

Alexander N. Shoushtari, MD, discusses the current role, benefits, and limitations of monitoring ctDNA in metastatic uveal melanoma.

Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.

Alexander Drilon, MD, discusses future directions for zidesamtinib in TKI-naive, ROS1-positive NSCLC following the ARROS-1 trial.

Alexander Drilon, MD, discusses phase 1/2 ARROS-1 efficacy and safety findings with zidesamtinib in TKI-naive, ROS1-positive NSCLC.

Frontline zidesamtinib produced a 94% response rate and 100% intracranial response rate in TKI-naive ROS1-positive advanced NSCLC.

JBS-003 will be evaluated in an ongoing phase 3 trial designed to determine whether investigators can identify patients who can safely receive less radiation.

Komal Jhaveri, MD, FACP, discusses the design of the SERENA-6 trial and larger questions for the breast cancer field that remain after seeing its results.

Michael J. Morris, MD, discusses key ongoing clinical trials in prostate cancer.

Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.

Michael J. Morris, MD, discusses updated data from the phase 3 PSMAddition trial supporting lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA-positive mHSPC.

Michael J. Morris, MD, discusses the FDA approval of lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA+ mHSPC.

Michael J. Morris, MD, discusses phase 3 PSMAddition trial data supporting lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA-positive mHSPC.

Komal Jhaveri, MD, FACP, discusses the role of CDK4/6 inhibitors for patients with hormone receptor–positive disease and how oral SERD use is changing.

Michael J. Morris, MD, discusses the significance of the FDA approval of lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA+ mHSPC.

Hamza Hashmi, MD, outlines considerations for identifying patients with early relapsed/refractory multiple myeloma as candidates for CAR T-cell therapy.

Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.

Lorenzo Falchi, MD, discusses key unmet needs and important next steps for diffuse large B-cell lymphoma research.

Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.

Alan L. Ho, MD, PhD, discusses an upcoming phase 3 trial evaluating Oz-V in OPSCC and key aspects of its design.

Christian Grommes, MD, discusses how BTK inhibitors and CAR T-cell therapy fit into the relapsed/refractory primary CNS lymphoma treatment paradigm.

The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.

Michael A. Postow, MD, discusses the current evidence gaps surrounding the management of irAEs in melanoma in the long term.